Coronary-artery bypass surgery (CABG) with CPB Surgery Coronary artery bypass graft (CABG)
Conditions
Interventions
Placebo or Amiodarone 600 mg/day for seven days orally and 45 mg/hour intravenously (IV) for 48 hours after the start of surgery
Sponsors
Medical University of Vienna, Department of Cardiology (Austria)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients older than 40 years and younger than 75 years old undergoing non-emergent coronary-artery bypass surgery (CABG) with CPB were eligible for the study
Exclusion criteria
Exclusion criteria: 1. A history of adverse events to AMIO 2. Concurrent treatment with AMIO within four months of enrolment 3. The use of antiarrhythmic therapy other than beta-receptor blockers 4. Calcium channel blockers or digitalis 5. A C-reactive protein (CRP) concentration above normal (>0.5 mg/dl) 6. A serum asparate aminotransferase or an alanine aminotransferase concentration four times the upper limit 7. Child bearing potential 8. An untreated thyroid dysfunction (thyroid-stimulating hormone [TSH] 10 miU/ml) 9. Chronic renal failure (serum creatinine >114 µmol/l) 10. An ejection fraction <30% (determined either by nuclear, left flourescence ventriculography or echocardiography) 11. Diabetes mellitus 12. Unstable angina 13. A resting heart rate of less than 50 beats per minute 14. An active infection 15. Malignancy 16. Chronic atrial fibrillation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-reactive protein concentration area under the curve (AUC) up to 48 hours after start of surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| AUCs of white blood cell count (WBC), fasting blood glucose (FBG), tumour necrosis factor-alpha (TNF-alpha), interleukin 6 and interleukin 10. | — |
Countries
Austria
Outcome results
None listed